Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
50
RGC Quote, Financials, Valuation and Earnings
Last price:
$29.36
Seasonality move
:
2545.92%
Day range:
$29.00 - $33.66
52-week range:
$0.11 - $83.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
989.66x
Volume:
160.5K
Avg. volume:
501.8K
1-year change:
26935.54%
Market cap:
$14.4B
Revenue:
--
EPS (TTM):
-$0.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $21.11 |
|
LJUIF
SSY Group Ltd.
|
-- | -- | -- | -- | -- |
|
SBMFF
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings Ltd.
|
$29.17 | -- | $14.4B | -- | $0.00 | 0% | -- |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
$0.07 | -- | $672.8M | -- | $0.00 | 0% | 0.95x |
|
HCM
HUTCHMED (China) Ltd.
|
$15.29 | $21.11 | $2.6B | 4.92x | $0.00 | 0% | 4.42x |
|
LJUIF
SSY Group Ltd.
|
$0.40 | -- | $1.2B | 14.08x | $0.01 | 4.63% | 2.02x |
|
SBMFF
Sino Biopharmaceutical Ltd.
|
$0.84 | -- | $15B | 30.49x | $0.01 | 1.37% | 3.57x |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 20.934 | -- | -- |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
-- | 0.000 | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.259 | -- | 4.41x |
|
LJUIF
SSY Group Ltd.
|
33.22% | -0.277 | -- | 2.03x |
|
SBMFF
Sino Biopharmaceutical Ltd.
|
23.1% | 0.898 | -- | 1.14x |
|
UNBSF
Uni-Bio Science Group
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CKLSF
CK Life Sciences International (Holdings), Inc.
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
LJUIF
SSY Group Ltd.
|
-- | -- | 12.86% | 19.05% | -- | -- |
|
SBMFF
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | -- | -- |
Regencell Bioscience Holdings Ltd. vs. Competitors
-
Which has Higher Returns RGC or CKLSF?
CK Life Sciences International (Holdings), Inc. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat CK Life Sciences International (Holdings), Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings Ltd.-- -- -- CKLSFCK Life Sciences International (Holdings), Inc.-- -- -- -
What do Analysts Say About RGC or CKLSF?
Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CK Life Sciences International (Holdings), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings Ltd. has higher upside potential than CK Life Sciences International (Holdings), Inc., analysts believe Regencell Bioscience Holdings Ltd. is more attractive than CK Life Sciences International (Holdings), Inc..
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings Ltd.0 0 0 CKLSFCK Life Sciences International (Holdings), Inc.0 0 0 -
Is RGC or CKLSF More Risky?
Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CK Life Sciences International (Holdings), Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RGC or CKLSF?
Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CK Life Sciences International (Holdings), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. CK Life Sciences International (Holdings), Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or CKLSF?
Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than CK Life Sciences International (Holdings), Inc. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than CK Life Sciences International (Holdings), Inc.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while CK Life Sciences International (Holdings), Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 0.95x for CK Life Sciences International (Holdings), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings Ltd.-- -- -- -- CKLSFCK Life Sciences International (Holdings), Inc.0.95x -- -- --
-
Which has Higher Returns RGC or HCM?
HUTCHMED (China) Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings Ltd.-- -- -- HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About RGC or HCM?
Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $21.11 which suggests that it could grow by 38.03%. Given that HUTCHMED (China) Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings Ltd.0 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is RGC or HCM More Risky?
Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.83%.
-
Which is a Better Dividend Stock RGC or HCM?
Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or HCM?
Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while HUTCHMED (China) Ltd.'s PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 4.42x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings Ltd.-- -- -- -- HCMHUTCHMED (China) Ltd.4.42x 4.92x -- --
-
Which has Higher Returns RGC or LJUIF?
SSY Group Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat SSY Group Ltd.'s return on equity of 19.05%.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings Ltd.-- -- -- LJUIFSSY Group Ltd.-- -- $1.4B -
What do Analysts Say About RGC or LJUIF?
Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand SSY Group Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings Ltd. has higher upside potential than SSY Group Ltd., analysts believe Regencell Bioscience Holdings Ltd. is more attractive than SSY Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings Ltd.0 0 0 LJUIFSSY Group Ltd.0 0 0 -
Is RGC or LJUIF More Risky?
Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SSY Group Ltd. has a beta of 0.039, suggesting its less volatile than the S&P 500 by 96.073%.
-
Which is a Better Dividend Stock RGC or LJUIF?
Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SSY Group Ltd. offers a yield of 4.63% to investors and pays a quarterly dividend of $0.01 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. SSY Group Ltd. pays out 48.86% of its earnings as a dividend. SSY Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RGC or LJUIF?
Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than SSY Group Ltd. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than SSY Group Ltd.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while SSY Group Ltd.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 2.02x for SSY Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings Ltd.-- -- -- -- LJUIFSSY Group Ltd.2.02x 14.08x -- --
-
Which has Higher Returns RGC or SBMFF?
Sino Biopharmaceutical Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat Sino Biopharmaceutical Ltd.'s return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings Ltd.-- -- -- SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B -
What do Analysts Say About RGC or SBMFF?
Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe Regencell Bioscience Holdings Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings Ltd.0 0 0 SBMFFSino Biopharmaceutical Ltd.0 0 0 -
Is RGC or SBMFF More Risky?
Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical Ltd. has a beta of 0.733, suggesting its less volatile than the S&P 500 by 26.711%.
-
Which is a Better Dividend Stock RGC or SBMFF?
Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical Ltd. offers a yield of 1.37% to investors and pays a quarterly dividend of $0.01 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. Sino Biopharmaceutical Ltd. pays out 65.96% of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RGC or SBMFF?
Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than Sino Biopharmaceutical Ltd. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than Sino Biopharmaceutical Ltd.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while Sino Biopharmaceutical Ltd.'s PE ratio is 30.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 3.57x for Sino Biopharmaceutical Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings Ltd.-- -- -- -- SBMFFSino Biopharmaceutical Ltd.3.57x 30.49x -- --
-
Which has Higher Returns RGC or UNBSF?
Uni-Bio Science Group has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat Uni-Bio Science Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings Ltd.-- -- -- UNBSFUni-Bio Science Group-- -- -- -
What do Analysts Say About RGC or UNBSF?
Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Uni-Bio Science Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings Ltd. has higher upside potential than Uni-Bio Science Group, analysts believe Regencell Bioscience Holdings Ltd. is more attractive than Uni-Bio Science Group.
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings Ltd.0 0 0 UNBSFUni-Bio Science Group0 0 0 -
Is RGC or UNBSF More Risky?
Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Uni-Bio Science Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RGC or UNBSF?
Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Uni-Bio Science Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. Uni-Bio Science Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or UNBSF?
Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than Uni-Bio Science Group quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than Uni-Bio Science Group's net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while Uni-Bio Science Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus -- for Uni-Bio Science Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings Ltd.-- -- -- -- UNBSFUni-Bio Science Group-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
